IMMX — Immix Biopharma Balance Sheet
0.000.00%
- $368.72m
- $352.78m
Annual balance sheet for Immix Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.391 | 17.6 | 13.4 | 17.5 | 17.7 |
| Net Total Receivables | 0.127 | 0.026 | 0.256 | 1.17 | 1.97 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.532 | 18.2 | 14.9 | 19.8 | 20.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.007 | 0.006 | 0.004 | 0.05 | 2.73 |
| Other Long Term Assets | |||||
| Total Assets | 0.54 | 18.2 | 14.9 | 19.9 | 22.9 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.27 | 0.202 | 1.27 | 3.72 | 8.69 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.27 | 0.202 | 1.75 | 3.52 | 9.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -4.73 | 18 | 13.2 | 16.4 | 13.3 |
| Total Liabilities & Shareholders' Equity | 0.54 | 18.2 | 14.9 | 19.9 | 22.9 |
| Total Common Shares Outstanding |